In addition to CD8+ T cells, SCFAs, particularly butyrate, enhance RT efficacy by promoting anti‐tumour immunity through the activation of dendritic cells (DCs) and macrophages, triggering improved antigen presentation and immune system activation.87, 88. This evidence concerns the gene CD8A and neoplasm.